Synergistic Active Targeting to B16F10 Tumors by αvβ3/CD44-Targeted Nanoparticles Loaded with Docetaxel

  • Sanjun Shi
Protocol
Part of the Methods in Pharmacology and Toxicology book series (MIPT)

Abstract

Generally, many drugs including nanomedicine can permeate into a superficial layer of tumors through an enhanced permeability and retention (EPR) effect. However, blood-tumor barrier negatively impacts permeation and accumulation of therapeutic drugs. The active targeting of nanoparticles to tumor endothelial cells (TECs) constitutes a breakthrough for overcoming this stint. Based on integrin αvβ3 (a highly specific TEC biomarker) and CD44 (a biomaker for tumor cells), a synergistic active targeting delivery system is able to target not only tumor blood vessels but also tumor cells. Therefore, a specific ligand of αvβ3, tetraiodothyroacetic acid (tetrac) and a major ligand of CD44, hyaluronan (HA), are employed to decorate on the surface of solid lipid nanoparticles (TeHA-SLNs). As a result, the docetaxel-loaded TeHA-SLNs (TeHA-SLNs/DTX) exhibit an excellent anti-tumor effect in vitro and in vivo through synergistic active-targeting function. This chapter gives an introduction to and discussion of the commonly used production and synthetic methods for tetrac conjugated HA and TeHA-SLNs/DTX. Moreover, the methods for characterization and cell targeting assessment in a αvβ3- and CD44-enriched B16F10 cell line are described. Finally, methods to assess targeting effects and antitumor activity of TeHA-SLNs/DTX in vivo are described.

Keywords

CD44 Dual-targeting delivery system Integrin αvβ3 Nanoparticle Synergistic active targeting 

Notes

Acknowledgment

This work is supported by the project of the National Natural Science Foundation of China (81402876) and the Program for “1135” Excellent Talents in Daping Hospital. We also would like to thank Prof. Zhirong Zhang and Xun Sun from Sichuan University for providing B16F10 cell line.

References

  1. 1.
    Hida K, Maishi N, Sakurai Y, Hida Y, Harashima H (2016) Heterogeneity of tumor endothelial cells and drug delivery. Adv Drug Deliv Rev 99:140–147CrossRefGoogle Scholar
  2. 2.
    Song W, Tang Z, Zhang D, Yu H, Chen X (2015) Coadministration of vascular disrupting agents and nanomedicines to eradicate tumors from peripheral and central regions. Small 11:3755–3761CrossRefGoogle Scholar
  3. 3.
    Kratz F, Elsadek B (2012) 8-Clinical impact of serum proteins on drug delivery. J Control Release 161:429–445CrossRefGoogle Scholar
  4. 4.
    Koopaei MN, Dinarvand R, Amini M, Rabbani H, Emami S, Ostad SN et al (2011) 9-Docetaxel immunonanocarriers as targeted delivery systems for HER 2-positive tumor cells: preparation, characterization, and cytotoxicity studies. Int J Nanomedicine 6:1903–1912PubMedPubMedCentralGoogle Scholar
  5. 5.
    Duro-Castano A, Gallon E, Decker C, Vicent MJ (2017) Modulating angiogenesis with integrin-targeted nanomedicines. Adv Drug Deliv Rev, https://doi.org/10.1016/j.addr.2017.05.008
  6. 6.
    Arosio D, Casagrande C (2016) Advancement in integrin facilitated drug delivery. Adv Drug Deliv Rev 97:111–143CrossRefGoogle Scholar
  7. 7.
    Rothdiener M, Beuttler J, Messerschmidt SK, Kontermann RE (2010) 10-Antibody targeting of nanoparticles to tumor-specific receptors: immunoliposomes. Methods Mol Biol 624:295–308CrossRefGoogle Scholar
  8. 8.
    Jeong JH, Lee M, Kim WJ, Yockman JW, Park TG, Kim YH et al (2005) 11-Anti-GAD antibody targeted non-viral gene delivery to islet beta cells. J Control Release 107:562–570CrossRefGoogle Scholar
  9. 9.
    Zhu L, Chen L, Cao QR, Chen D, Cui J (2011) 12-Preparation and evaluation of mannose receptor mediated macrophage targeting delivery system. J Control Release 152(Suppl 1):e190–e191CrossRefGoogle Scholar
  10. 10.
    Jain A, Agarwal A, Majumder S, Lariya N, Khaya A, Agrawal H et al (2010) 13-Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 148:359–367CrossRefGoogle Scholar
  11. 11.
    Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW et al (2006) 14-Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci U S A 103:6315–6320CrossRefGoogle Scholar
  12. 12.
    Xiang D, Zheng C, Zhou SF, Qiao S, Tran PH, Pu C et al (2015) Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors. Theranostics 5:1083–1097CrossRefGoogle Scholar
  13. 13.
    Guo S, Lin CM, Xu Z, Miao L, Wang Y, Huang L (2014) 16-Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996–5009CrossRefGoogle Scholar
  14. 14.
    Brannon-Peppas L, Blanchette JO (2004) 17-Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 56:1649–1659CrossRefGoogle Scholar
  15. 15.
    Wang H, Zheng L, Peng C, Shen M, Shi X, Zhang G (2013) 18-Folic acid-modified dendrimer-entrapped gold nanoparticles as nanoprobes for targeted CT imaging of human lung adencarcinoma. Biomaterials 34:470–480CrossRefGoogle Scholar
  16. 16.
    El-Gogary RI, Rubio N, Wang JT, Al-Jamal WT, Bourgognon M, Kafa H et al (2014) 18″-Polyethylene glycol conjugated polymeric nanocapsules for targeted delivery of quercetin to folate-expressing cancer cells in vitro and in vivo. ACS Nano 8:1384–1401CrossRefGoogle Scholar
  17. 17.
    Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, Nielsen UB et al (2006) 24-Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66:6732–6740CrossRefGoogle Scholar
  18. 18.
    Choi CHJ, Alabi CA, Webster P, Davis ME (2010) 25-Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A 107:1235–1240CrossRefGoogle Scholar
  19. 19.
    Chen W, Jarzyna PA, van Tilborg GAF, Nguyen VA, Cormode DP, Klink A et al (2010) 26-RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. FASEB J 24:1689–1699CrossRefGoogle Scholar
  20. 20.
    Huang XH, Peng XH, Wang YQ, Wang YX, Shin DM, El-Sayed MA et al (2010) 27-A reexamination of active and passive tumor targeting by using rod-shaped gold Nanocrystals and covalently conjugated peptide ligands. ACS Nano 4:5887–5896CrossRefGoogle Scholar
  21. 21.
    Gianella A, Jarzyna PA, Mani V, Ramachandran S, Calcagno C, Tang J et al (2011) 28-Multifunctional nanoemulsion platform for imaging guided therapy evaluated in experimental cancer. ACS Nano 5:4422–4433CrossRefGoogle Scholar
  22. 22.
    Chattopadhyay N, Fonge H, Cai ZL, Scollard D, Lechtman E, Done SJ et al (2012) 29-Role of antibody-mediated tumor targeting and route of administration in nanoparticle tumor accumulation in vivo. Mol Pharm 9:2168–2179CrossRefGoogle Scholar
  23. 23.
    Prokopiou EM, Ryder SA, Walsh JJ (2013) 30-Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 16:503–524CrossRefGoogle Scholar
  24. 24.
    Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR et al (2013) 31-Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 8:137–143CrossRefGoogle Scholar
  25. 25.
    Kunjachan S, Pola R, Gremse F, Theek B, Ehling J, Moeckel D et al (2014) 32-Passive versus active tumor targeting using RGD- and NGR-modified polymeric nanomedicines. Nano Lett 14:972–981CrossRefGoogle Scholar
  26. 26.
    Mousa SA, Bergh JJ, Dier E, Rebbaa A, O’Connor LJ, Yalcin M et al (2008) 33-Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 11:183–190CrossRefGoogle Scholar
  27. 27.
    Bergh JJ, Lin HY, Lansing L, Mohamed SN, Davis FB, Mousa S et al (2005) 34-Integrin alpha(v)beta(3) contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 146:2864–2871CrossRefGoogle Scholar
  28. 28.
    Kang CM, Koo HJ, Lee S, Lee KC, Oh YK, Choe YS (2013) 35-Cu-64-labeled tetraiodothyroacetic acid-conjugated liposomes for PET imaging of tumor angiogenesis. Nucl Med Biol 40:1018–1024CrossRefGoogle Scholar
  29. 29.
    Brooks PC, Clark RA, Cheresh DA (1994) b-Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264:569–571CrossRefGoogle Scholar
  30. 30.
    Hood JD, Cheresh DA (2002) a-Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100CrossRefGoogle Scholar
  31. 31.
    Rebbaa A, Chu F, Davis FB, Davis PJ, Mousa SA (2008) 36-Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 11:269–276CrossRefGoogle Scholar
  32. 32.
    Qhattal HSS, Hye T, Alali A, Liu XL (2014) 37-Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano 8:5423–5440CrossRefGoogle Scholar
  33. 33.
    Huang JB, Zhang H, Yu Y, Chen Y, Wang D, Zhang GQ et al (2014) 38-Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials 35:550–566CrossRefGoogle Scholar
  34. 34.
    Shi SJ, Han L, Deng L, Zhang YL, Shen HX, Gong T et al (2014) 41-Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release 194:228–237CrossRefGoogle Scholar
  35. 35.
    Shi SJ, Han L, Gong T, Zhang ZR, Sun X (2013) 42-Systemic delivery of microRNA-34a for cancer stem cell therapy. Angew Chem Int Ed 52:3901–3905CrossRefGoogle Scholar
  36. 36.
    Wada T, Chirachanchai S, Izawa N, Inaki Y, Takemoto K (1994) 51-Synthesis and properties of hyaluronic acid conjugated nucleic acid analogs-1: synthesis of deacetylhyaluronan and introduction of nucleic acid bases. J Bioact Compat Polym 9:429–447CrossRefGoogle Scholar
  37. 37.
    Crescenzi V, Francescangeli A, Renier D, Bellini D (2002) 52-New cross-linked and sulfated derivatives of partially deacetylated hyaluronan: synthesis and preliminary characterization. Biopolymers 64:86–94CrossRefGoogle Scholar
  38. 38.
    Šimkovic I, Hricovınia M, Šoltés L, Mendichi R, Cosentino C (2000) Preparation of water-soluble/insoluble derivatives of hyaluronic acid by cross-linking with epichlorohydrin in aqueous NaOH/NH4OH solution. Carbohydr Polym 41:9–14CrossRefGoogle Scholar
  39. 39.
    Shi S, Zhou M, Li X, Hu M, Li C, Sheng F, Li Z, Wu G et al (2016) Synergistic active targeting of dually integrin αvβ3/CD44-targeted nanoparticles to B16F10 tumors located at different sites of mouse bodies. J Control Release 235:1–13CrossRefGoogle Scholar
  40. 40.
    Bitter T, Muir HM (1962) A modified uronic acid carbazole reaction. Anal Biochem 4:330–334CrossRefGoogle Scholar
  41. 41.
    Yin H, Zhao F, Zhang DH, Li J (2015) B-Hyaluronic acid conjugated beta-cyclodextrin-oligoethylenimine star polymer for CD44-targeted gene delivery. Int J Pharm 483:169–179CrossRefGoogle Scholar
  42. 42.
    Taherian A, Li XL, Liu YQ, Haas TA (2011) C-Differences in integrin expression and signaling within human breast cancer cells. BMC Cancer 11:293CrossRefGoogle Scholar
  43. 43.
    Miao W, Shim G, Kang CM, Lee S, Choe YS, Choi HG, Oh YK (2013) Cholesteryl hyaluronic acid-coated, reduced graphene oxide nanosheets for anti-cancer drug delivery. Biomaterials 34:9638–9647CrossRefGoogle Scholar
  44. 44.
    Wang YG, Yang TY, Wang X, Dai WB, Wang JC, Zhang XA, Li ZQ, Zhang QA (2011) Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J Control Release 149:299–306CrossRefGoogle Scholar
  45. 45.
    Shen J, Yin Q, Chen L, Zhang Z, Li Y (2012) Co-delivery of paclitaxel and survivin shRNA by pluronic P85-PEI/TPGS complex nanoparticles to overcome drug resistance in lung cancer. Biomaterials 33:8613–8624CrossRefGoogle Scholar
  46. 46.
    Emanuele S, Lauricella M, Carlisi D, Vassallo B, D’Anneo A, Di Fazio P et al (2007) SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Apoptosis 12:1327–1338CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2018

Authors and Affiliations

  • Sanjun Shi
    • 1
  1. 1.Department of Pharmacy, Institute of Surgery Research, Daping HospitalThird Military Medical UniversityChongqingPeople’s Republic of China

Personalised recommendations